Ernexa Therapeutics Inc.
ERNA
$1.39
-$0.10-6.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 43.23% | -23.39% | 6.40% | -375.84% | -22.65% |
| Total Depreciation and Amortization | -90.48% | -87.25% | -85.86% | -12.77% | 817.46% |
| Total Amortization of Deferred Charges | -- | -- | 1,139.44% | 2,263.46% | -- |
| Total Other Non-Cash Items | 127.04% | 525.48% | 57.88% | 8,109.74% | -23.23% |
| Change in Net Operating Assets | -128.88% | -76.94% | -404.70% | -206.35% | 5,252.94% |
| Cash from Operations | -12.08% | 44.89% | 23.94% | -7.88% | 41.66% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | -- |
| Total Debt Issued | -- | 60.14% | -100.00% | -55.40% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | 0.00% |
| Other Financing Activities | -- | -- | -77.63% | 100.00% | -- |
| Cash from Financing | 22,504.55% | 62.74% | -86.89% | -54.48% | -107.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 194.74% | 107.69% | -183.83% | -189.06% | 28.93% |